OFF-LABEL USE AND MISUSE OF TESTOSTERONE, GROWTH HORMONE, THYROID HORMONE, AND ADRENAL SUPPLEMENTS: RISKS AND COSTS OF A GROWING PROBLEM
- PMID: 32163313
- DOI: 10.4158/PS-2019-0540
OFF-LABEL USE AND MISUSE OF TESTOSTERONE, GROWTH HORMONE, THYROID HORMONE, AND ADRENAL SUPPLEMENTS: RISKS AND COSTS OF A GROWING PROBLEM
Abstract
Over the past few decades, there has been an unprecedented rise in off-label use and misuse of testosterone, growth hormone, thyroid hormone, and adrenal supplements. Testosterone therapy is often promoted to men for the treatment of low energy, lower libido, erectile dysfunction, and other symptoms. Growth hormone is used in attempts to improve athletic performance in athletes and to attenuate aging in older adults. Thyroid hormone and/or thyroid supplements or boosters are taken to treat fatigue, obesity, depression, cognitive impairment, impaired physical performance, and infertility. Adrenal supplements are used to treat common nonspecific symptoms due to "adrenal fatigue," an entity that has not been recognized as a legitimate medical diagnosis. Several factors have contributed to the surge in off-label use and misuse of these hormones and supplements: direct-to-consumer advertising, websites claiming to provide legitimate medical information, and for-profit facilities promoting therapies for men's health and anti-aging. The off-label use and misuse of hormones and supplements in individuals without an established endocrine diagnosis carries known and unknown risks. For example, the risks of growth hormone abuse in athletes and older adults are unknown due to a paucity of studies and because those who abuse this hormone often take supraphysiologic doses in sporadic intervals. In addition to the health risks, off-label use of these hormones and supplements generates billions of dollars of unnecessary costs to patients and to the overall health-care system. It is important that patients honestly disclose to their providers off-label hormone use, as it may affect their health and treatment plan. General medical practitioners and adult endocrinologists should be able to begin a discussion with their patients regarding the unfavorable balance between the risks and benefits associated with off-label use of testosterone, growth hormone, thyroid hormone, and adrenal supplements. Abbreviations: DHEA = dehydroepiandrosterone; FDA = U.S. Food and Drug Administration; GH = growth hormone; IGF-1 = insulin-like growth factor 1; LT3 = L-triiodothyronine; LT4 = levothyroxine; T3 = total triiodothyronine; T4 = thyroxine; TSH = thyroid-stimulating hormone.
Comment in
-
Off-Label Use and Misuse of Hormone Supplements: AACE and ACE Position Statement.Am Fam Physician. 2020 Dec 15;102(12):759-760. Am Fam Physician. 2020. PMID: 33320505 No abstract available.
Similar articles
-
Pharmacokinetics of L-Triiodothyronine in Patients Undergoing Thyroid Hormone Therapy Withdrawal.Thyroid. 2019 Oct;29(10):1371-1379. doi: 10.1089/thy.2019.0101. Epub 2019 Sep 12. Thyroid. 2019. PMID: 31364488 Free PMC article. Clinical Trial.
-
ITALIAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS STATEMENT-REPLACEMENT THERAPY FOR PRIMARY HYPOTHYROIDISM: A BRIEF GUIDE FOR CLINICAL PRACTICE.Endocr Pract. 2016 Nov;22(11):1319-1326. doi: 10.4158/EP161308.OR. Epub 2016 Aug 2. Endocr Pract. 2016. PMID: 27482609 Review.
-
A prospective study on endocrine function in patients with long-COVID symptoms.Hormones (Athens). 2024 Mar;23(1):59-67. doi: 10.1007/s42000-023-00511-0. Epub 2023 Nov 24. Hormones (Athens). 2024. PMID: 37996650
-
Growth hormone administration stimulates energy expenditure and extrathyroidal conversion of thyroxine to triiodothyronine in a dose-dependent manner and suppresses circadian thyrotrophin levels: studies in GH-deficient adults.Clin Endocrinol (Oxf). 1994 Nov;41(5):609-14. doi: 10.1111/j.1365-2265.1994.tb01826.x. Clin Endocrinol (Oxf). 1994. PMID: 7828350
-
Obesity in the ageing man.Metabolism. 2013 Oct;62(10):1341-9. doi: 10.1016/j.metabol.2013.05.019. Epub 2013 Jul 5. Metabolism. 2013. PMID: 23831443 Review.
Cited by
-
Growth hormone-receptor disruption in mice reduces osteoarthritis and chondrocyte hypertrophy.Geroscience. 2024 Oct;46(5):4895-4908. doi: 10.1007/s11357-024-01230-z. Epub 2024 Jun 3. Geroscience. 2024. PMID: 38831184 Free PMC article.
-
Harm Reduction in Male Patients Actively Using Anabolic Androgenic Steroids (AAS) and Performance-Enhancing Drugs (PEDs): a Review.J Gen Intern Med. 2021 Jul;36(7):2055-2064. doi: 10.1007/s11606-021-06751-3. Epub 2021 May 4. J Gen Intern Med. 2021. PMID: 33948794 Free PMC article. Review.
-
Adult Growth Hormone Deficiency: Diagnostic and Treatment Journeys From the Patients' Perspective.J Endocr Soc. 2022 May 12;6(7):bvac077. doi: 10.1210/jendso/bvac077. eCollection 2022 Jul 1. J Endocr Soc. 2022. PMID: 35673404 Free PMC article.
-
The Dark Side of hormone prescription.Endocr Connect. 2021 Aug 26;10(9):C1-C3. doi: 10.1530/EC-21-0039. Endocr Connect. 2021. PMID: 34348235 Free PMC article. No abstract available.
-
Thyroid hormone signaling is associated with physical performance, muscle mass, and strength in a cohort of oldest-old: results from the Mugello study.Geroscience. 2021 Apr;43(2):1053-1064. doi: 10.1007/s11357-020-00302-0. Epub 2020 Nov 21. Geroscience. 2021. PMID: 33219914 Free PMC article.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous